Primary thyroid cancers including papillary, follicular, poorly differentiated, and anaplastic carcinomas show substantial differences in biological and clinical behaviors. Even in the same pathological type, there is wide variability in the clinical course of disease progression. The molecular carcinogenesis of thyroid cancer has advanced tremendously in the last decade. However, specific inhibition of oncogenic pathways did not provide a significant survival benefit in advanced progressive thyroid cancer that is resistant to radioactive iodine therapy. Accumulating evidence clearly shows that cellular energy metabolism, which is controlled by oncogenes and other tumor-related factors, is a critical factor determining the clinical phenotypes of cancer. However, the role and nature of energy metabolism in thyroid cancer remain unclear. In this article, we discuss the role of cellular energy metabolism, particularly mitochondrial energy metabolism, in thyroid cancer. Determining the molecular nature of metabolic remodeling in thyroid cancer may provide new biomarkers and therapeutic targets that may be useful in the management of refractory thyroid cancers.

Citations

Citations to this article as recorded by  

• Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review
  Angelika Buczyńska, Maria Kościuszko, Adam Jacek Krętowski, Anna Popławska-Kita
  Frontiers in Pharmacology.2024;[Epub]     CrossRef
• Liquid Biopsy as a Method for Minimally Invasive Diagnosis of Thyroid Cancer
  Tagir I. Rakhmatullin, Mark Jain, Larisa M. Samokhodskaya, Vladimir A. Zhivotov
  Journal of Clinical Practice.2023; 14(3): 69.     CrossRef
• Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
  Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong
  Endocrinology and Metabolism.2022; 37(1): 53.     CrossRef
• Monensin Inhibits Anaplastic Thyroid Cancer via Disrupting Mitochondrial Respiration and AMPK/mTOR Signaling
  Yanli Li, Qianshu Sun, Sisi Chen, Xiongjie Yu, Hongxia Jing
  Anti-Cancer Agents in Medicinal Chemistry.2022; 22(14): 2539.     CrossRef
• Growth Differentiation Factor 15 is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness
  Yea Eun Kang, Jin Man Kim, Mi Ae Lim, Seong Eun Lee, Shinae Yi, Jung Tae Kim, Chan Oh, Lihua Liu, Yanli Jin, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Jeong Ho Lee, Hyun Jung Kim, Hyun Yong Koh, Sangmi Jun, Sun Wook Cho, Minho Shong, Bon Seok Koo
  Thyroid.2021; 31(5): 772.     CrossRef
• Clinical Significance of the D-Loop Gene Mutation in Mitochondrial DNA in Laryngeal Cancer
  Lei Wang, He-Xiang Cheng, Yan-Hui Zhou, Min Ma
  OncoTargets and Therapy.2021; Volume 14: 3461.     CrossRef
• Transcriptomic and Genetic Associations between Alzheimer’s Disease, Parkinson’s Disease, and Cancer
  Jaume Forés-Martos, Cesar Boullosa, David Rodrigo-Domínguez, Jon Sánchez-Valle, Beatriz Suay-García, Joan Climent, Antonio Falcó, Alfonso Valencia, Joan Anton Puig-Butillé, Susana Puig, Rafael Tabarés-Seisdedos
  Cancers.2021; 13(12): 2990.     CrossRef
• KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma
  Zheng Wang, Xinguang Qiu, Hao Zhang, Weihan Li
  Journal of Biochemical and Molecular Toxicology.2020;[Epub]     CrossRef
• Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma
  Ruben D. Addie, Sarantos Kostidis, Willem E. Corver, Jan Oosting, Sepideh Aminzadeh-Gohari, René G. Feichtinger, Barbara Kofler, Mehtap Derya Aydemirli, Martin Giera, Hans Morreau
  Scientific Reports.2020;[Epub]     CrossRef
• Inhibition of mitochondrial respiration by tigecycline selectively targets thyroid carcinoma and increases chemosensitivity
  Yuehua Wang, Fei Xie, Dejie Chen, Ling Wang
  Clinical and Experimental Pharmacology and Physiology.2019; 46(10): 890.     CrossRef
• Investigating Therapeutic Effects of Retinoic Acid on Thyroid Cancer via Protein-Protein Interaction Network Analysis
  Majid Rezaei-Tavirani, Mostafa Rezaei-Tavirani, Mona Zamanian Azodi
  International Journal of Cancer Management.2019;[Epub]     CrossRef
• CASE REPORT: An Extensively Necrotic Hürthle-Cell Carcinoma Mimicked a Thyroid Abscess
  Sanders H. Lin, Shih-Ming Huang, Su-Lin Peng
  Clinical Thyroidology.2018; 30(11): 529.     CrossRef
• Atovaquone enhances doxorubicin’s efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer
  Zhuo Lv, Xintong Yan, Liying Lu, Chun Su, Yin He
  Journal of Bioenergetics and Biomembranes.2018; 50(4): 263.     CrossRef
• Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma
  Xianyin Lai, Christopher B. Umbricht, Kurt Fisher, Justin Bishop, Qiuying Shi, Shaoxiong Chen
  Journal of Proteomics.2017; 166: 59.     CrossRef
• Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer
  Marika H Tesselaar, Johannes W Smit, James Nagarajah, Romana T Netea-Maier, Theo S Plantinga
  Journal of Molecular Endocrinology.2017; 59(4): R141.     CrossRef
• Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis
  Nurul-Syakima Ab Mutalib, Sri Noraima Othman, Azliana Mohamad Yusof, Shahrun Niza Abdullah Suhaimi, Rohaizak Muhammad, Rahman Jamal
  PeerJ.2016; 4: e2119.     CrossRef